Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | TACR2 | P21452 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SHBG | P04278 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | TST | Q16762 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313200 | 1.00 | HTR2A (0.60) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL9945668 | 1.00 | HTR2A (0.60) | HTR2AESR1ADRA2AADORA3TACR2 | |
| Hydrochloric Acid SCHEMBL11737570 | 0.98 | HTR2A (0.58) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL19174795 | 0.98 | HTR2A (0.57) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL29342921 | 0.92 | HTR2A (0.50) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL11686889 | 0.92 | HTR2A (0.50) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL29342569 | 0.92 | HTR2A (0.50) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL30469503 | 0.86 | HTR2A (0.62) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL6861225 | 0.86 | HTR2A (0.62) | HTR2AESR1ADRA2AADORA3TACR2 | |
| Hydrochloric Acid SCHEMBL27998571 | 0.86 | HTR2A (0.62) | HTR2AESR1ADRA2AADORA3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303250-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING1 MULTIPLE SCLEROSIS | Novartis AG (CH) | 2011-04-06 | — | — | EP | claimed |
| US-20140274897-A1 | METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN | EVOTEC INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-8772233-B2 | Method for promoting regeneration of pancreatic beta-cells by administering neurturin | EVOTEC INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130150293-A1 | METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20110256113-A1 | METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN | EVOTEC INTERNATIONAL GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| WO-2011080733-A1 | DEPOT SYSTEMS COMPRISING GLATIRAMER OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MAPI PHARMA LIMITED (IL) | 2011-07-07 | — | — | WO | disclosed |
| EP-2303250-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING1 MULTIPLE SCLEROSIS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2268603-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-2- [2- (4-C3-C21-ALKYL-PHENYL)ETHYL]PROPANE-1, 3-DIOLS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100158874-A1 | Compositions and Methods for Treating Peripheral Vascular Diseases | MOUNT SINAI HOSPITAL (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20090298771-A1 | USE OF SECRETED PROTEIN PRODUCTS FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20080241106-A1 | Using nervous system protein to induce stem cell differentiation into pancreatic tissues; tissue engineering and repair; regenerative medicine; | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1971363-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | Waratah Pharmaceuticals, Inc. (CA) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008104064-A1 | COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASES | MOUNT SINAI HOSPITAL (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104065-A1 | NEURAL CELL PREPARATIONS AND METHODS OF MAKING AND USING THEM | MOUNT SINAI HOSPITAL (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007062531-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20070110728-A1 | Method for preventing and treating diabetes using dg119 | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-5948820-A | IMMUNOSUPPRESSANT; PREVENT REJECTION OF ORGAN TRANSPLANT;AUTOIMMUNE DISEASES; MULTIPLE SCLEROSIS; LUPUS; ANTIALLERGENS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |